Trials / Completed
CompletedNCT05486377
Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
Efficacy and Safety of Remimazolam vs. Inhalational Anesthetics for General Anesthesia for the Ablation of Arrhythmia: Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam besylate | Remimazolam besylate TIVA |
Timeline
- Start date
- 2022-08-02
- Primary completion
- 2023-05-19
- Completion
- 2023-05-19
- First posted
- 2022-08-03
- Last updated
- 2023-08-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05486377. Inclusion in this directory is not an endorsement.